Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone acetonide (Pacira BioSciences)
- Development stage
- Phase 3
- Lead developer
- Pacira BioSciences
- Modality
- Small Molecules
- Administration
- Intraarticular
01
Overview
FX006 (Zilretta) is an extended-release, intra-articular formulation of triamcinolone acetonide, a synthetic corticosteroid. Developed using a proprietary poly(lactic-co-glycolic acid) (PLGA) microsphere technology, it is designed to provide sustained pain relief by maintaining therapeutic concentrations of the drug within the joint space for an extended period. Triamcinolone acetonide acts as a potent agonist of the glucocorticoid receptor, leading to the suppression of inflammatory cytokines and mediators. While Zilretta is FDA-approved for the management of osteoarthritis pain of the knee, FX006 has been evaluated in Phase 2 clinical trials (such as the RANGE study) for other indications, including glenohumeral osteoarthritis and adhesive capsulitis (frozen shoulder). The formulation aims to overcome the rapid clearance typically seen with immediate-release corticosteroid injections.
- Brand names
- Zilretta
- Other names
- triamcinolone acetonide extended-release injectable suspensionTA-ER
02
Targets
GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on triamcinolone acetonide (Pacira BioSciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone acetonide (Pacira BioSciences).